Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer

被引：56

作者：

Popiela T. ^{[1
]}

Kulig J. ^{[1
]}

Czupryna A. ^{[1
]}

Szczepanik A.M. ^{[1
]}

Zembala M. ^{[2
]}

机构：

[1] First Dept. Surg. Gastrointest. S., Jagiellonian University, Medical College, Cracow

[2] Department of Clinical Immunology, Jagiellonian University, Medical College, 30-663 Cracow

来源：

Gastric Cancer | 2004年 / 7卷 / 4期

关键词：

BCG; Chemotherapy; FAM; Gastric cancer; Immunochemotherapy;

D O I：

10.1007/s10120-004-0299-y

中图分类号：

学科分类号：

摘要：

Background. Despite curative resection, 50%-90% of gastric cancer patients die of disease relapse. Although some clinical trials have indicated that chemotherapy and immunochemotherapy may be effective modalities, more recent studies have not been able to define the standard treatment for advanced gastric cancer. The present study evaluated the effect of adjuvant immunochemotherapy with the use of BCG (bacille Calmette-Guérin) and FAM (5-fluorouracil, adriamycin, mitomycin C) chemotherapy on the survival of patients with locally advanced resectable gastric cancer. Methods. A total of 156 patients with stage III or IV gastric cancer who had undergone curative resection were randomly assigned to three treatment groups: BCG + FAM (immunochemotherapy), FAM (chemotherapy), and control (surgery only). Treatment was continued for 2 years or until death. Further postsurgical follow up was carried on for up to 10 years. Results. Overall 10-year survival was 47.1% for the immunochemotherapy group (P < 0.037 vs FAM and P < 0.0006 vs control), 30% for the chemotherapy group (vs con-trol, NS), and 15.2% for the control group. In patients with pT2/T3 primary tumors, 10-year survival was 55.3% for BCG + FAM vs 28.2% for FAM (P < 0.01) and 14.6% for the control group (P < 0.00018). BCG + FAM significantly improved the survival of patients with intestinal-type but not diffuse-type cancer. Immunochemotherapy was well tolerated. Conclusion. This study, based on a hunted number of patients, indicates that adjuvant immunochemotherapy (BCG + FAM) may prolong the survival of gastric cancer patients after curative gastrectomy; in particular, in patients with pT2/ T3 tumors and intestinal-type primary tumors. There was no survival benefit from FAM adjuvant chemotherapy.

引用

页码：240 / 245

页数：5

共 28 条

[1]

Alberts S.R., Cervantes A., Van De Velde C.J., Gastric cancer: Epidemiology, pathology and treatment, Ann Oncol, 14, 2 SUPPL., pp. 31-36, (2003)

[2]

Macdonald J.S., Smalley S.R., Benedetti J., Hundahl S.A., Estes N.C., Stemmermann G.N., Et al., Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction, N Engl J Med, 345, pp. 725-730, (2001)

[3]

Grau J.J., Martin M., Fuster J., Pera M., Garcia-Valdecasas J.C., Bombi J.A., Et al., Impact of adjuvant chemotherapy in the long-term outcome of patients with resected gastric cancer, J Surg Oncol, 82, pp. 234-240, (2003)

[4]

Nashimoto A., Nakajima T., Furukawa H., Kitamura M., Kinoshita T., Yamamura Y., Et al., Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1, J Clin Oncol, 21, pp. 2282-2287, (2003)

[5]

Macdonald J.S., Schein P.S., Wooley P.V., 5 Fluorouracil, doxorubicin, mitomycin C (FAM) combination chemotherapy for advanced gastric cancer, Ann Intern Med, 93, pp. 533-536, (1980)

[6]

Mackall C.L., Fleisher T.A., Brown M.R., Andrich M.P., Chen C.C., Feuerstein I.M., Et al., Distinctions between CD8<sup>+</sup> and CD4<sup>+</sup> T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy, Blood, 89, pp. 3700-3707, (1997)

[7]

Ochiai T., Sato H., Hayashi R., Asano T., Sato H., Yamamura Y., Postoperative adjuvant immunotherapy of gastric cancer with BCG cell wall skeleton, Cancer Immunol Immunother, 14, pp. 167-171, (1983)

[8]

Lamm D.L., Optimal BCG treatment of superficial bladder cancer as defined by American trials, Eur Urol, 21, pp. 12-16, (1992)

[9]

Popiela T., Zembala M., Oszacki J., Jedrychowski W., A follow-up study on chemoimmunotherapy (5-fluorouracil and BCG) in advanced gastric cancer, Cancer Immunol Immunother, 13, pp. 182-184, (1982)

[10]

Fielding J.W., Roginski C., Ellis D.J., Jones B.G., Powell J., Waterhouse J.A., Et al., Clinicopathological staging of gastric cancer, Br J Surg, 71, pp. 677-680, (1984)

← 1 2 3 →